[Impact of preoperative locoregional chemotherapy with fluorodeoxyuridine on the outcome of liver resection]

Chir Ital. 2002 Nov-Dec;54(6):811-8.
[Article in Italian]

Abstract

The aim of the study was to evaluate the effects of preoperative intra-arterial hepatic chemotherapy (IAHC) on the outcome of liver resections for hepatic metastases from colorectal cancer. Twelve patients (IAHC group) treated by IAHC with fluorodeoxyuridine (FUdR) and subsequent liver resection and 40 patients who underwent liver resection without preliminary IAHC (non-IAHC group) were analysed comparatively in terms of age, gender, concomitant diseases, previous abdominal surgery, type of hepatic resection, use of portal clamping, and associated surgical procedures. For the purposes of the study, length of operation, intraoperative blood losses, perioperative transfusions, length of hospitalisation, complications and mortality were also recorded. The two groups were comparable (p = n.s.) for those variables affecting the perioperative course. As regards the end points of the study, no significant differences were recorded in length of operation, intraoperative blood losses, perioperative transfusions [except for more postoperative plasma transfusions in the IAHC group (16.7% vs 5.0%, p = 0.009)] and postoperative complications (9.1% vs 17.5%, p = 0.415). Postoperative mortality consisted in one patient in the IAHC group. Postoperative hospitalization was significantly longer in the non-IAHC group (median: 8 vs 10, range: 6-13 vs 5-33 days; p = 0.004). IAHC does not negatively affect the outcome of subsequent liver resection.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Colorectal Neoplasms / pathology
  • Combined Modality Therapy
  • Female
  • Floxuridine / administration & dosage*
  • Humans
  • Infusions, Intra-Arterial
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Preoperative Care*
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Floxuridine